Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
Representative image of breast cancer drug development, highlighting Avenzo Therapeutics’ ORION-1 trial of AVZO-023 and AVZO-021 in advanced HR+/HER2- metastatic breast cancer.
Pharma & Biotech

What Avenzo Therapeutics’ ORION-1 expansion reveals about the next phase of CDK drug development

Find out how Avenzo Therapeutics’ AVZO-023 and AVZO-021 combination study could influence HR+/HER2- breast cancer treatment.

Read More
Representative image of a clinical researcher reviewing rare disease therapy data, as Beren Therapeutics faces an extended FDA decision timeline for adrabetadex in infantile-onset Niemann-Pick disease type C.
Pharma & Biotech

Why the FDA extended its adrabetadex review and what it means for Beren Therapeutics

Adrabetadex faces a longer FDA review in infantile-onset NPC. The delay could shape rare-disease drug standards in 2026.

Read More
Representative image showing neuroscience-based psychiatric treatment research as Evecxia Therapeutics builds the case for EVX-101 as a potential adjunctive therapy for patients with depression, obsessive-compulsive disorder and inadequate SSRI response.
Pharma & Biotech

Can Evecxia Therapeutics turn EVX-101 into the first serotonin synthesis amplification therapy?

EVX-101 revives serotonin synthesis as an SSRI add-on strategy. Can Evecxia prove old biology still has new clinical value?

Read More
Representative image of neuropsychiatry drug research, highlighting Draig Therapeutics’ DT-101 Phase 1 data, AMPA receptor potentiation and the search for new major depressive disorder treatments.
Pharma & Biotech

Draig Therapeutics DT-101 Phase 1 data put MEG biomarkers at the centre of depression trials

DT-101 may revive AMPA receptor depression research, but Phase 2 must prove safety signals can become real clinical benefit.

Read More
Representative image of oncology researchers reviewing molecular therapy data, reflecting Pfizer and Innovent Biologics’ global collaboration to advance antibody-drug conjugates, multispecific antibodies, and next-generation cancer medicines.
Pharma & Biotech

Why Pfizer’s $10.5bn Innovent Biologics deal matters for the next wave of cancer medicines

Pfizer’s $10.5bn Innovent alliance deepens its oncology reset. Can early ADC and multispecific bets become global cancer drugs?

Read More
Representative image: AstraZeneca’s Imfinzi approval with BCG brings immunotherapy into earlier bladder cancer care, reshaping treatment options for high-risk non-muscle-invasive bladder cancer.
Pharma & Biotech

Imfinzi approval gives AstraZeneca a first immunotherapy combination in early bladder cancer

Imfinzi moves into early bladder cancer, but can AstraZeneca turn a DFS win into real-world bladder-preserving impact?

Read More
Representative image of next-generation vaccine research, showing how AAHI’s SLA-SE adjuvant technology is gaining attention through Eli Lilly and Company’s acquisition of Curevo Vaccine and its shingles vaccine candidate amezosvatein.
Pharma & Biotech

Lilly’s Curevo deal turns AAHI’s adjuvant science into a late-stage vaccine opportunity

Find out how AAHI’s SLA-SE adjuvant could shape Lilly’s next-generation shingles vaccine strategy after the Curevo acquisition.

Read More
Representative image: A clinical neuropsychiatry consultation setting reflects ReST Therapeutics’ move to advance RST-101 into human testing for early PTSD treatment.
Pharma & Biotech

ReST Therapeutics wins FDA IND acceptance for RST-101 as early PTSD treatment strategy enters human testing

ReST Therapeutics’ RST-101 enters human testing for early PTSD. Find out why this IND acceptance could reshape trauma care.

Read More
Representative image of a clinician preparing an injectable treatment in an outpatient care setting, illustrating Braeburn’s latest BRIXADI data on long-acting buprenorphine, opioid withdrawal suppression, and treatment retention in opioid use disorder.
Pharma & Biotech

Braeburn’s BRIXADI evidence package raises new questions for injectable buprenorphine adoption

Braeburn’s new BRIXADI data shows retention and dosing signals in opioid use disorder. Find out what it means for treatment strategy.

Read More
Representative image: Eli Lilly’s expanding diabetes and obesity drug pipeline, including Foundayo, Mounjaro and retatrutide, highlights the growing race to reshape cardiometabolic care through oral GLP-1 therapies, injectable incretin drugs and next-generation clinical trial advances.
Pharma & Biotech

Can Eli Lilly’s Foundayo and retatrutide deepen its grip on the diabetes and obesity market?

Find out how Eli Lilly’s Foundayo and retatrutide data could reshape diabetes, obesity and cardiometabolic care.

Read More